NK cell therapy
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
Artiva Pursues IPO to Fund NK Cell Therapy After Losing Merck Partnership
Artiva, Merck, IPO, NK Cell Therapy, Biotech, Partnership, Funding